Glucose deprivation is associated with Chk1 degradation through the ubiquitin-proteasome pathway and effective checkpoint response to replication blocks

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 6, 2011, Pages 1230-1238

  Kim, Ae Jeong ^a   Kim, Hyun Ju ^a   Jee, Hye Jin ^a   Song, Naree ^a   Kim, Minjee ^a   Bae, Yoe Sik ^b   Chung, Jay H ^c   Yun, Jeanho ^a  

^a Dong A University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Chk1; Genomic instability; Glucose deprivation; Protein stability; Ubiquitin proteasome pathway

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; GLUCOSE; MYC PROTEIN; PROTEASOME; UBIQUITIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA REPLICATION; ENZYME DEGRADATION; FIBROBLAST; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UBIQUITINATION;

BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME STABILITY; GLUCOSE; HEK293 CELLS; HELA CELLS; HEP G2 CELLS; HUMANS; LEUPEPTINS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SERINE; SIGNAL TRANSDUCTION; TIME FACTORS; UBIQUITIN; UBIQUITINATION;

MAMMALIA;

EID: 79955675611     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.03.012     Document Type: Article

References (47)

1. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
2. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
3. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., Lubratovich M., Verselis S.J., Isselbacher K.J., Fraumeni J.F., Birch J.M., Li F.P., Garber J.E., Haber D.A. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531.
4. Bertoni F., Codegoni A.M., Furlan D., Tibiletti M.G., Capella C., Broggini M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosom. Cancer 1999, 26:176-180.
5. Walworth N., Davey S., Beach D. Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature 1993, 363:368-371.
6. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Carattini-Rivera S., DeMayo F., Bradley A., Donehower L.A., Elledge S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. 2000, 14:1448-1459.
7. Boddy M.N., Furnari B., Mondesert O., Russell P. Replication checkpoint enforced by kinases Cds1 and Chk1. Science 1998, 280:909-912.
8. Zeng Y., Forbes K.C., Wu Z., Moreno S., Piwnica-Worms H., Enoch T. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature 1998, 395:507-510.
9. Takai H., Tominaga K., Motoyama N., Minamishima Y.A., Nagahama H., Tsukiyama T., Ikeda K., Nakayama K., Nakanishi M., Nakayama K. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev. 2000, 14:1439-1447.
10. Lam M.H., Liu Q., Elledge S.J., Rosen J.M. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004, 6:45-59.
11. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 2001, 21:4129-4139.
12. den Elzen N.R., O'Connell M.J. Recovery from DNA damage checkpoint arrest by PP1-mediated inhibition of Chk1. EMBO J. 2004, 23:908-918.
13. Leung-Pineda V., Ryan C.E., Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol. Cell. Biol. 2006, 26:7529-7538.
14. Lu X., Nannenga B., Donehower L.A. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005, 19:1162-1174.
15. Collis S.J., Barber L.J., Clark A.J., Martin J.S., Ward J.D., Boulton S.J. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat. Cell Biol. 2007, 9:391-401.
16. Feng J.M., Zhu H., Zhang X.W., Ding J., Miao Z.H. Proteasome-dependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity. Cancer Biol. Ther. 2008, 7.
17. Leung-Pineda V., Huh J., Piwnica-Worms H. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res. 2009, 69:2630-2637.
18. Zhang Y.W., Brognard J., Coughlin C., You Z., Dolled-Filhart M., Aslanian A., Manning G., Abraham R.T., Hunter T. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol. Cell 2009, 35:442-453.
19. Zhang Y.W., Otterness D.M., Chiang G.G., Xie W., Liu Y.C., Mercurio F., Abraham R.T. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell 2005, 19:607-618.
20. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 2004, 14:198-206.
21. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49:6449-6465.
22. Gullino P.M. Extracellular Compartments of Solid Tumors 1975, Vol. 3. Plenum Press, New York.
23. Mueller-Klieser W., Walenta S. Geographical mapping of metabolites in biological tissue with quantitative bioluminescence and single photon imaging. Histochem. J. 1993, 25:407-420.
24. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
25. Yuan J., Glazer P.M. Mutagenesis induced by the tumor microenvironment. Mutat. Res. 1998, 400:439-446.
26. Rockwell S., Yuan J., Peretz S., Glazer P.M. Genomic instability in cancer. Novartis Found. Symp. 2001, 240:133-142. discussion 142-151.
27. Kim M.A., Kim H.J., Brown A.L., Lee M.Y., Bae Y.S., Park J.I., Kwak J.Y., Chung J.H., Yun J. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif. Exp. Mol. Med. 2007, 39:205-212.
28. Yun J., Lee W.H. Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage. Mol. Cell. Biol. 2003, 23:7305-7314.
29. Kaneko Y.S., Watanabe N., Morisaki H., Akita H., Fujimoto A., Tominaga K., Terasawa M., Tachibana A., Ikeda K., Nakanishi M. Cell-cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 1999, 18:3673-3681.
30. Lukas C., Bartkova J., Latella L., Falck J., Mailand N., Schroeder T., Sehested M., Lukas J., Bartek J. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 2001, 61:4990-4993.
31. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
32. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70:503-533.
33. Coux O., Tanaka K., Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996, 65:801-847.
34. Fenech M. Cytokinesis-block micronucleus assay evolves into a "cytome" assay of chromosomal instability, mitotic dysfunction and cell death. Mutat. Res. 2006, 600:58-66.
35. Iarmarcovai G., Bonassi S., Botta A., Baan R.A., Orsiere T. Genetic polymorphisms and micronucleus formation: a review of the literature. Mutat. Res. 2008, 658:215-233.
36. Rodriguez-Bravo V., Guaita-Esteruelas S., Florensa R., Bachs O., Agell N. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells. Cancer Res. 2006, 66:8672-8679.
37. Alchanati I., Teicher C., Cohen G., Shemesh V., Barr H.M., Nakache P., Ben-Avraham D., Idelevich A., Angel I., Livnah N., Tuvia S., Reiss Y., Taglicht D., Erez O. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target. PLoS ONE 2009, 4:e8104.
38. Liu Q.Y., Lei J.X., Sikorska M., Liu R. A novel brain-enriched E3 ubiquitin ligase RNF182 is up regulated in the brains of Alzheimer's patients and targets ATP6V0C for degradation. Mol Neurodegener 2008, 3:4.
39. Wei S., Yang H.C., Chuang H.C., Yang J., Kulp S.K., Lu P.J., Lai M.D., Chen C.S. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. J. Biol. Chem. 2008, 283:26759-26770.
40. Yun J., Kim Y.I., Tomida A., Choi C.H. Regulation of DNA topoisomerase IIalpha stability by the ECV ubiquitin ligase complex. Biochem. Biophys. Res. Commun. 2009, 389:5-9.
41. Walenta S., Schroeder T., Mueller-Klieser W. Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol. Eng. 2002, 18:249-262.
42. Moulder J.E., Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987, 5:313-341.
43. Yuan J., Narayanan L., Rockwell S., Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 2000, 60:4372-4376.
44. Mihaylova V.T., Bindra R.S., Yuan J., Campisi D., Narayanan L., Jensen R., Giordano F., Johnson R.S., Rockwell S., Glazer P.M. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol. 2003, 23:3265-3273.
45. Papp-Szabo E., Josephy P.D., Coomber B.L. Microenvironmental influences on mutagenesis in mammary epithelial cells. Int. J. Cancer 2005, 116:679-685.
46. Shahrzad S., Quayle L., Stone C., Plumb C., Shirasawa S., Rak J.W., Coomber B.L. Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res. 2005, 65:8134-8141.
47. Jardim M.J., Wang Q., Furumai R., Wakeman T., Goodman B.K., Wang X.F. Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. Mol. Biol. Cell 2009, 20:3801-3809.